Overall impact
B (80)

Commentary

Repligen is a strong overall performer. With a 'B' rating of 79.9 for overall impact (94th percentile compared to all companies), Repligen ranks 53rd out of 585 industry peers, behind Amgen, Regeneron Pharmaceuticals, Cell Source and 49 others, and ahead of Grifols, Biogen, Ionis Pharmaceuticals and 529 others. On top material causes for Repligen's industry (Pharmaceuticals & Biotech), Repligen performs well in Reduced Waste (83.0 score), Reduced Green House Gas Emissions (83.4), Improved Mental Health (82.0) and 7 other causes where it received an 'A' score and performs poorly in Equal Pay and Opportunity (37.3 score).
Impact
Cause RGEN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2,000
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Medical Equipment & Supplies
Headquarters
Ma, United States
Share classes
RGEN
Description
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins, as well as cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics, and OPUS smaller-scale columns that are used in high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Material causes
Ethos considers the following causes material for Repligen, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.